In Situ Cross-Linkable High Molecular Weight Hyaluronan−Bisphosphonate Conjugate for Localized Delivery and Cell-Specific Targeting: A Hydrogel Linked Prodrug Approach
- 5 June 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 131 (25) , 8781-8783
Abstract
We present here a novel synthesis route to functionalize high molecular weight hyaluronan (HMW-HA) with a hydrazide group and a bioactive ligand, namely bisphosphonate (BP). For this purpose, a new symmetrical self-immolative biscarbazate linker has been devised. The hydrazide group was used to form hydrazone cross-linked hydrogel upon treating with previously described aldehyde modified hyaluronan. The 1:1 weight ratio of these two polymers gave hydrogel in less than 30 s. In this communication we present the first in vitro results showing that even though HA can target CD44 positive cancer cells (HCT-116), receptor mediated endocytosis could only occur by cleavage of high molecular weight HA with an ubiquitous enzyme, hyaluronidase (Hase). The cancer cells are known to overexpress CD44 receptors and also increase the hyaluronidase activity in vivo. Thus the pro-drug design, based on drug conjugation to HMW-HA, represents a new drug delivery platform where the drug potency is triggered by Hase mediated degradation of the HA-drug conjugate. We have successfully demonstrated that the cross-linkable HA−BP conjugate first undergoes Hase-mediated scission to the fragments of suitable sizes so as to be internalized by CD44 positive cells. The specificity of this targeting was proven by comparing the results with less CD44 positive HEK-293T cells. The localized delivery of such drugs at the surgical resection site opens up avenues to control tumor recurrence after removal of the tumor. In the form of hydrogel it would prevent systemic exposure of the drug and would allow its controlled release.Keywords
This publication has 27 references indexed in Scilit:
- Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomesJournal of Controlled Release, 2008
- The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosisApoptosis, 2008
- Delivery of Doxorubicin from Biodegradable PEG Hydrogels Having Schiff Base Linkages†Journal of Bioactive and Compatible Polymers, 2007
- Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogelsJournal of Controlled Release, 2007
- Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4Journal of Cell Science, 2007
- F-16438s, Novel Binding Inhibitors of CD44 and Hyaluronic AcidThe Journal of Antibiotics, 2006
- A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomasProceedings of the National Academy of Sciences, 2006
- Aryldithioethyloxycarbonyl (Ardec): A New Family of Amine Protecting Groups Removable under Mild Reducing Conditions and Their Applications to Peptide SynthesisChemistry – A European Journal, 2006
- Extracellular Protease Activation of Chemotherapeutics from Hydrogel Matrices: A New Paradigm for Local ChemotherapyMolecular Pharmaceutics, 2005
- Synthesis of AminobisphosphonateSynthetic Communications, 1996